|
Amsterdam Molecular Therapeutics |
|
|
Meibergdreef 61
Amsterdam, 1105 BA Netherlands
phone:(31) (0) 20 566 7394
fax:(31) (0) 20 566 9272
|
|
| Symbol |
AMT |
| Exchange |
Euronext |
| Founded |
1998 |
| Employees |
85 |
|
|
| www.amtbiopharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Established a safe and effective gene delivery approach and a unique process that enables the economic, commercially scalable manufacturing of gene therapy products. |
|
| Management |
| Jorn Aldag, CEO;
Piers Morgan, CFO |
| |
|
|
|
|
|
|
|
| Keywords |
| gene therapy, gene delivery, Glybera, lipoprotein lipase deficient, LPLD, vector technology |
|
|
|
| Description |
|
AMT has established a safe and effective gene delivery approach and a unique process that enables the economic, commercially scaleable manufacturing of gene therapy products. This powerful platform combined with the research expertise of our collaboration partners provides AMT with exciting opportunities to deliver more curative therapies to patients faster.
AMT's lead product, Glybera, is in registration with EMA for the treatment of lipoprotein lipase deficient (LPLD) patients. LPLD is a seriously debilitating, and potentially lethal, orphan disease, for which no approved therapy exists today. |
|
| Products / Services |
Glybera is the leading gene therapy product in development today.
|
|
| Technology / Differentiation |
| AMT uses its AAV vector technology and proprietary know-how to overcome the challenges which have previously held-back the development of safe, effective, scaleable, lasting gene therapy. |
|
| Market / Customers |
Global. AMT targets areas where there is either no existing therapy, or where the current standard of care provides only symptomatic relief and there exists a clear unmet medical need for a treatment to modify the disease.
|
|
| Status |
| Lead product in registration for LPLD.
Hemophilia B program in Phase I/II study.
Other programs targeting Duchenne Muscular Dystrophy, Parkinson's Disease and Acute Intermittent Porphyria are in pre-clinical development. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
